Floatz logo

LENVATINIB

Malignant Neoplasms of Digestive Organs

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

73 Active assets in the Malignant Neoplasms of Digestive Organs cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 2BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Brian Anderson, MD
Phase 4BB
Irinotecan
Amgen
Phase 2BB
DEXAMETHASONE
Cedars-Sinai Medical Center
Phase 4BB
Mlf 541
B. Braun Melsungen AG
Phase 3BB

View all 50 →

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →